Novartis stock falls nearly 4% as heart-drug failure deepens setbacks
It had earlier halted trials of an experimental cell therapy; rival Amgen's share price also hit.
See all — The Straits Times →Aggregated from the leading newsrooms of the country. Every story links to its original source.







